The aim of this prospective study was to determine whether treatment with a combination of GM-CSF and erythropoietin (rhEpo) can improve the anemia associated with low risk myelodysplastic syndrome (MDS), namely refractory anemia (RA), RA with ring sideroblasts (RAS), and RA with excess of blasts (RAEB) with bone marrow blasts less than 10%. Eligibility criteria included an Hb level of less than 10.5 g/dl for newly diagnosed patients, or symptomatic anemia. GM-CSF was given at a dose of 3 g/kg s.c. on days 1-2, rhEpo at a dose of 60 U/kg s.c. on days 3-5. No treatment was given on days 6-7. Patients were followed-up with full blood count on a weekly basis. The treatment was repeated for a total of 6 weeks. At that time, if a rise in Hb above 1.5 g/dl had not been achieved, the dose of rhEpo increased to 120 U/kg. Post-treatment evaluation was performed at the completion of 12 weeks. Erythroid response was defined as good (GR), if an increase in untransfused Hb values above 2 g/dl or a 100% decrease in red blood cell transfusion requirements, over the treatment period was observed, while an increase in untransfused Hb values 1-2 g/dl or a Ͼ50% decrease in transfusion requirements, were considered as partial response. Responders continued to receive the same treatment until disease progression. Nineteen patients (13 male and six female) with a median age of 69 years were enrolled in the study. The FAB subtypes were: RA one case, RAS eight cases and RAEB 10 cases. Ten of 19 patients (52.6%) responded to the treatment: 7/19 (36.8%) achieved a GR and 3/19 (15.8%) a PR. Six of eight (75%) patients with RAS, one case with RA and 3/10 (30%) of cases with RAEB responded to treatment. Pretreatment serum epo levels were generally low (less than 200 Mu/ml) in responding patients. At the completion of the initial 12 weeks, 8/12 responding patients (5 RAS, 2 RAEB and 1 RA) continued to receive the same treatment. All responding patients with RAS continued to show an erythroid response in a time period from 3 to 24 months, whilst one patient with RA and two with RAEB did not have a continuing response at 2, 4 and 12 months, respectively. The above data suggest that the combination of rhEpo and GM-CSF should be recommended in all cases with RARS. However, the clear indication of this combination for other patients with MDS remains to be determined.
Introduction
Analysis of large series of myelodysplastic syndromes (MDS) based on the FAB classification or on the proposed scoring systems, [1] [2] [3] [4] [5] suggest that patients with refractory anemia (RA), RA with ringed sideroblasts (RARS) and RA with excess of blasts (RAEB) with bone marrow (BM) blasts less than 10%, have an indolent course and low incidence of acute leukemia. However, the major problem for these patients is anemia resulting in red blood cells transfusion on a regular basis.
During the last few years recombinant erythropoietin (rhEpo) has been used in clinical trials for the treatment of MDS. The overall response rate has been variable ranging from 0 to 63%, but a recent metanalysis 6 showed that the efficacy of rhEpo in the treatment of anemia in MDS is around 20%. The response rate was better in patients with RA and RAEB (21%) as compared with a response rate of only 8% for patients with RARS.
Recent reports on the treatment of MDS with rhEpo in combination with G-CSF or GM-CSF have suggested that such combinations are more effective than rhEpo alone. [7] [8] [9] In particular, response rates are relatively high for patients with RARS. These results indicate that there is a synergistic effect between rhEpo and G-CSF or GM-CSF. However, the treatment of MDS with the combination of cytokines is an expensive approach while the therapeutic indications are not well defined. The recently introduced predictive scoring system to erythroid response 10 is an important contribution to the subject. The combination of rhEpo and GM-CSF has been studied in limited number of cases. 9 The results of this study are promising, although there is a question about the identification of subgroups of patients with favorable response and about the optimal duration and dose of the combination.
The object of this prospective study was to determine whether the treatment of low risk MDS (RA, RARS, and RAEB with BM blasts less than 10%) with a combination of rhEpo and GM-CSF can improve ineffective erythropoiesis associated with MDS.
Patients and methods
Between October 1995 and April 1998, 19 patients with a low risk MDS namely RA, RAS and RAEB, classified according to FAB criteria, were enrolled in the study.
In 12 patients the treatment was started within the first month from diagnosis while in the remaining seven patients within a median time of 6.5 months (range 3-25).
Patients were not previously treated (apart from blood transfusion) with the exception of one patient who had lowdose aracytine 20 months before entry into the trial.
Patients with RA and RARS, and RAEB with BM blasts Ͻ10% and age Ͼ60 years were treated. Patients with RAEB with BM blasts Ͼ10% and those with RAEBt are currently treated in our unit with combined chemotherapy supported with GM-CSF. 11 However patients with the latter subgroups, who failed to respond, or patients in whom administration of chemotherapy was contraindicated were included in this study, provided that the course of chemotherapy was given at least 2 months previously. Eligibility criteria included an Hb level Ͻ10.5 g/dl for newly diagnosed patients, hematocrit Ͻ30% or symptomatic anemia. The age limits were up to 80 years. Patients were excluded if they had a serum creatinine greater than 180 mol/l, Karnofsky score Ͻ50%, hepatocellular enzyme levels Ͼ2.5 × normal.
The study was submitted and approved by the local ethics committee. The possible beneficial and side-effects of the treatment were discussed with the patients and finally written informed consent was obtained from all of them.
Study design
At enrollment, seven patients were transfusion dependent and the treatment started within a median time of 6.5 months from diagnosis (range 3-25 months). In the remaining 12 patients treatment started within approximately 1 month from diagnosis.
The whole treatment schedule was planned to be given 5 days weekly for the convenience of the patients also taking into consideration that smaller doses of GM-CSF, as was given in the study, might produce a beneficial response with decreased extramedullary constitutional side-effects. 12 GM-CSF was given at a dose of 3 g/kg s.c. on days 1-2, rhEpo at a dose of 60 U/kg s.c. on days 3-5. No treatment was given on days 6-7. The treatment was repeated for a total of 6 weeks. At that time if a rise in Hb above 1.5 g/dl had not been achieved, the dose of rhEpo increased to 120 U/kg.
Post-treatment evaluation was performed at the completion of 12 weeks. Laboratory investigation before treatment included baseline hematologic parameters, liver function tests, serum immunoglobulins, serum lactase dehydrogenase, serum ferritin, serum Epo, bone marrow aspirate and biopsy and cytogenetics.
Patients were followed up with blood counts and reticulocytes on a weekly basis. Bone marrow aspirate and biopsy were performed after 6 weeks of treatment and at the end of treatment schedule after 12 weeks.
Erythroid response was defined as being a good response (GR), partial response (PR) and no response (NR). A GR was defined as an increase in untransfused Hb values of Ͼ2 g/dl or a 100% decrease in red blood cells transfusion requirements over the treatment period, while an increase in untransfused Hb values 1-2 g/dl or a Ͼ50% decrease in transfusion requirements were considered as PR. 7 Responders continued to receive the same treatment until disease progression.
Statistical analysis was performed using Pearson's chisquare test, Student's t-test and one-way analysis of variance (ANOVA). Level of statistical significance was set to be equal to 5%.
Results

Patients
Thirteen males and six females with a median age of 69 years (range 50-80) enrolled. The MDS subtypes were: RA one case, RARS eight cases and RAEB 10 cases. Patient's pretreatment characteristics are summarized in Table 1 . All patients completed the study and were eligible for evaluation.
Erythroid response:
Ten out of 19 patients (52.6%) responded to treatment. Seven (36.8%) achieved a GR and three (15.8%) a PR. Among the FAB subtypes 6/8 (75%) with RARS (5 GR, 1 PR), three (30%) with RAEB (2 GR, 1 PR) and the only case with RA (PR) responded to treatment. In the seven cases with GR and two with PR the response was noted during the first 6 weeks at the dose of rhEpo 60 U/kg. In only one case with PR the response was noted after the escalation of rhEpo at the dose of 120 U/kg. Pretreatment serum epo levels were generally low (less than 200 mu/ml) in responders but there was not a statistically significant association between response and the levels of ferritin and LDH at the onset of treatment.
Blood values:
The median WBC and neutrophil values during the 12 weeks of treatment (counts were performed weekly) were significantly increased compared to pretreatment levels (P = 0.017 and P = 0.006, respectively). Platelets were not significantly affected by the treatment. However, thrombocytopenia during treatment was developed in two cases. Both cases did not respond to treatment and transformed to acute leukemia in 3 and 8 months, respectively. Finally the combination of GM-CSF and rhEpo did not affect BM blasts at 6 and 12 weeks. Blood values after treatment are presented in detail in Table 2 .
Follow-up:
At the completion of the initial 12 weeks of treatment, eight out of 10 responding patients (5 RARS, 1 RA, 2 RAEB) continued to receive the same treatment. All responding patients with RARS continued to show an erythroid response within a time period from 3 to 24 months (median 11 months), while one patient with RA and two with RAEB did not have a continuing response at 2, 4 and 12 months, respectively.
The duration of PR in the cases of RA and RAEB was 2 and 4 months, respectively. In the case of RARS, PR continues for 26 months. However, in this case the patient continues treatment with GM-CSF and rhEpo, but not on regular basis.
With a median follow-up period of 22 months, 5/10 patients with RAEB transformed to acute myeloid leukemia (AML). The transformation was observed in four non-responders within a median time of 8 months (range 3-16 months) upon completion of treatment and in one case with GR within 12 months from the onset of treatment, while the patient was on maintenance treatment.
The probability of transformation to AML was not significantly different between responders and non responders (P = 0.07).
Side effects:
The observed side-effects were minor. Flulike syndrome in a patient with RAEB, headache and low fever in four patients (two with RAEB and two with RARS) and arthralgias in one patient with RARS.
Discussion
Most patients with MDS are elderly with other concurrent medical problems which complicate their management. In the vast majority supportive treatment with red blood cells and platelet transfusions, as well as the treatment of infections, have been the mainstay of therapy. Multidrug chemotherapy proved to be of important value for high risk patients (RAEB or RAEBt) although therapy-related morbidity and mortality remain the major problem for these cases. 11, 13 Patients with low risk MDS have generally an indolent course but gradually they become transfusion-dependent, making the improvement of anemia by stimulation of normal erythropoiesis an important goal of their management. The introduction of rhEpo into clinical practice provided a new therapeutic approach for MDS patients but the overall response rate, regarding improvement of anemia, is about 20%, 6 the lower response rate being noticed in RARS patients.
The relatively low erythroid response rates obtained in MDS patients using rhEpo alone led to investigation of the possibility of synergistically increasing erythropoiesis by combining rhEpo with other growth factors such as G-CSF and GM-CSF. [7] [8] [9] The efficacy of rhEpo may be increased by the addition of one of the above cytokines which also act on early precursors. In particular GM-CSF is a multipotential hemopoietin that promotes not only proliferation and differentiation of granulocytes and macrophages, but also stimulates the formation of erythroid progenitor cell. 14, 15 The results of the combination of G-CSF and rhEpo indicated that there is a real synergistic effect between the two factors, as the overall response rate of MDS patients with this combination is higher than with rhEpo alone. Furthermore, an interesting finding is that patients with RARS have a high response rate (around 45%) to this combination compared to 8% with rhEpo alone. 7, 8 The combination of GM-CSF and rhEpo, has been studied in limited number of cases. 9 In the present prospective study low risk MDS patients were treated with a combination of rhEpo and GM-CSF. GM-CSF was given on days 1-2 before rhEpo administration which was given for the 3 subsequent days.
The results of this study showed a high response rate (36.8% GR and 15.8% PR) in MDS patients overall. The majority of patients and particularly responders, in the current study belonged to the group with high probability of erythroid response according to the predictive model. 10 However, an interesting finding was that this combination proved very effective in the treatment of RARS cases, since six out of eight patients responded. Furthermore, all responding patients with RARS continued to show an erythroid response receiving the same treatment within a time period from 3 to 24 months.
The results of the present series are comparable to those of other reports, 7, 8 where the combination of rhEPO and G-CSF produce similar response rates in MDS patients overall and higher response rates in the subgroup of RARS in particular.
All patients have shown an erythroid response with relatively small doses of rhEpo in combination with GM-CSF, with the exception of one case where escalation of the dose of rhEpo was required. The schedule of the two cytokine administration, in the present series, was generally well tolerated and no substantial changes in the percentage of BM blasts were noted in the cases of RAEB. None of the patients progressed to overt AML during the treatment period, however 5/10 cases of RAEB developed AML later on. Four of them were non-responders and the transformation was observed within a median time of 8 months from the onset of treatment. The fifth patient was a good responder and the transformation occurred within 12 months from the onset of treatment while on maintenance treatment. Although the transformation rate in this group appears high, this might be a coincidence due to the small number of patients.
In summary, the results of the present prospective study in low risk MDS treated with the combination of rhEpo and GM-CSF, showed that the erythroid response rate was relatively high. In particular, erythroid response and the duration of response were higher in patients with RARS. This is an important aspect indicating a synergistic effect between the two factors. The above data, as well as those of other studies, 7, 8 suggest that the combination of rhEpo with G-CSF or GM-CSF should be recommended in all cases with RARS. The predictive scoring system introduced recently 10 should be used for selecting patients from other subgroups of MDS to be treated with the combination of cytokines.
